Showing results (141-150 of 164) with videos related to
Sort By:
Pageof 17
European Heart Journal|November 10, 2000
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trialL Rydén, P W Armstrong, J G Cleland, et al.The American Journal of Cardiology|September 15, 1988
Left ventricular response to submaximal and maximal exercise in asymptomatic aortic regurgitationR A Wilson, B H Greenberg, B M Massie, et al.Circulation|March 15, 1995
Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophyB M Massie, S Schaefer, J Garcia, et al.JAMA|November 9, 1994
Management of heart failure. II. Counseling, education, and lifestyle modificationsK Dracup, D W Baker, S B Dunbar, et al.Journal of Cardiac Failure|May 9, 1998
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial InvestigatorsB M Massie, J G Cleland, P W Armstrong, et al.Journal of the American College of Cardiology|November 15, 1994
Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsJ S Gottdiener, D J Reda, B J Materson, et al.European Journal of Heart Failure|December 13, 2000
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study GroupM J Sculpher, L Poole, J Cleland, et al.Journal of Cardiac Failure|September 21, 2000
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant PhysiciansJ A Franciosa, W T Abraham, M Fowler, et al.Circulation|January 1, 1992
Response of high-energy phosphates and lactate release during prolonged regional ischemia in vivoS Schaefer, G G Schwartz, J A Wisneski, et al.Circulation|December 11, 1999
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study GroupM Packer, P A Poole-Wilson, P W Armstrong, et al.Pageof 17